Contact
searchSearch
HMP Global

Medical Therapies

Featured Content

Research Highlights
Combination Biologic and Small-Molecule Therapy Shows Promise in Refractory IBD, Meta-Analysis Finds
01/14/2026
Jessica Garlewicz
The findings of a new analysis highlight both the potential and the caution required when considering dual-targeted therapy in patients who fail to respond to monotherapy.
The findings of a new analysis highlight both the potential and the caution required when considering dual-targeted therapy in patients who fail to respond to monotherapy.
The findings of a new analysis...
01/14/2026
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
Study Highlights Antibody Development and Dosing Concerns in Older IBD Patients on Infliximab
01/20/2025
Jessica Garlewicz
Dosing decisions for infliximab should prioritize disease activity and patient-specific factors rather than chronological age alone.
Dosing decisions for infliximab should prioritize disease activity and patient-specific factors rather than chronological age alone.
Dosing decisions for infliximab...
01/20/2025
Advances in Inflammatory Bowel Disease Network
News
Standard Dosing of Infliximab Effective for Steroid-Refractory ASUC
10/18/2024
Jessica Garlewicz
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and...
10/18/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Guselkumab for Moderate to Severe Ulcerative Colitis
09/12/2024
Rebecca Mashaw
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab...
09/12/2024
Advances in Inflammatory Bowel Disease Network
Christina Ha
Video
Christina Ha, MD, on the Role of Anti-interleukins in IBD
09/10/2024
Christina Ha, MD
Dr Ha reviews her presentation from the AIBD regional on the safety and efficacy of interleukin 12/23 and interleukin 23 in the management of Crohn's disease and ulcerative colitis.
Dr Ha reviews her presentation from the AIBD regional on the safety and efficacy of interleukin 12/23 and interleukin 23 in the management of Crohn's disease and ulcerative colitis.
Dr Ha reviews her presentation...
09/10/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Erin Forster, MD, on Risankizumab for Ulcerative Colitis
09/03/2024
Erin Forster, MD, MPH; Millie D. Long, MD, MPH; Raymond Cross, MD
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical...
09/03/2024
Advances in Inflammatory Bowel Disease Network
News
Subcutaneous Ustekinumab Cost Rose 84% Under Medicare Part D, Set to Drop Under Negotiated Price Reduction
08/15/2024
Rebecca Mashaw
Coverage changes omitted self-injected therapies from Part B, HHS Inspector General Reports
Coverage changes omitted self-injected therapies from Part B, HHS Inspector General Reports
Coverage changes omitted...
08/15/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Requires Warning Label Change for Thiopurines
08/13/2024
Rebecca Mashaw
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare...
08/13/2024
Advances in Inflammatory Bowel Disease Network

News

FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
Standard Dosing of Infliximab Effective for Steroid-Refractory ASUC
10/18/2024
Jessica Garlewicz
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and...
10/18/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Guselkumab for Moderate to Severe Ulcerative Colitis
09/12/2024
Rebecca Mashaw
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab...
09/12/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Requires Warning Label Change for Thiopurines
08/13/2024
Rebecca Mashaw
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare...
08/13/2024
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib vs Tofacitinib for Clinical Remission in Ulcerative Colitis
08/09/2024
Jolynn Tumolo
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a...
08/09/2024
Advances in Inflammatory Bowel Disease Network
News
FDA Approves Interchangeable Biosimilar for Ustekinumab
11/02/2023
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved...
11/02/2023
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Mirikizumab for Adults With Moderately to Severely Active Ulcerative Colitis
10/27/2023
Rebecca Mashaw
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated...
10/27/2023
Advances in Inflammatory Bowel Disease Network
News
FDA Approves New Oral Treatment for Ulcerative Colitis
10/13/2023
Priyam Vora
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug...
10/13/2023
Advances in Inflammatory Bowel Disease Network
Research Highlights
Combined Ultrasound and Calprotectin at 3 Months Predict Postoperative Recurrence in Crohn’s Disease
05/07/2026
Jessica Garlewicz
High specificity and positive predictive value suggest that patients meeting both thresholds are at high risk for early recurrence and may need closer monitoring.
High specificity and positive predictive value suggest that patients meeting both thresholds are at high risk for early recurrence and may need closer monitoring.
High specificity and positive...
05/07/2026
Advances in Inflammatory Bowel Disease Network
News
Oral Icotrokinra Demonstrates Efficacy in Ulcerative Colitis Regardless of Prior Advanced Therapy Exposure
05/05/2026
Jessica Garlewicz
While response rates were generally higher in patients without prior advanced therapy failure, meaningful improvements were still seen in those with treatment-resistant disease.
While response rates were generally higher in patients without prior advanced therapy failure, meaningful improvements were still seen in those with treatment-resistant disease.
While response rates were...
05/05/2026
Advances in Inflammatory Bowel Disease Network
Research Review
Early “Top-Down” Therapy Reduces Long-Term Complications in Crohn’s Disease
05/05/2026
Jessica Garlewicz
Disease progression and hospitalizations were more common in the step-up group, with higher rates of stricturing and penetrating complications.
Disease progression and hospitalizations were more common in the step-up group, with higher rates of stricturing and penetrating complications.
Disease progression and...
05/05/2026
Advances in Inflammatory Bowel Disease Network
Research Review
Upper GI Crohn’s Disease Remains Underrecognized, Lacks Standardized Guidance
04/02/2026
Jessica Garlewicz
A recent review noted a lack of consistent diagnostic definitions across modalities, complicating clinical interpretation and research comparisons.
A recent review noted a lack of consistent diagnostic definitions across modalities, complicating clinical interpretation and research comparisons.
A recent review noted a lack of...
04/02/2026
Advances in Inflammatory Bowel Disease Network
Research Summary
Advanced Therapy May Reduce Antibiotic Dependence in Chronic Pouchitis After IPAA
03/18/2026
Jessica Garlewicz
These findings support considering immune-mediated therapy in selected patients although more research is needed to identify the patients likely to benefit most from advanced therapy.
These findings support considering immune-mediated therapy in selected patients although more research is needed to identify the patients likely to benefit most from advanced therapy.
These findings support...
03/18/2026
Advances in Inflammatory Bowel Disease Network
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
News
Medicare Will Cover GLP-1s for Obesity Under Deal with Pharma
11/06/2025
Rebecca Mashaw
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said...
11/06/2025
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Concomitant Medications Do Not Alter Efficacy of Advanced Therapies in Ulcerative Colitis, Study Finds
09/18/2025
Jessica Garlewicz
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Persistent Prothrombotic State Observed in Patients With ASUC
09/04/2025
Rebecca Mashaw
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with...
09/04/2025
Advances in Inflammatory Bowel Disease Network

Insights

IBD Drive time logo
Podcast
IBD Drive Time: Erin Forster, MD, on Risankizumab for Ulcerative Colitis
09/03/2024
Erin Forster, MD, MPH; Millie D. Long, MD, MPH; Raymond Cross, MD
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical...
09/03/2024
Advances in Inflammatory Bowel Disease Network
Shubha Bhat
Podcast
Shubha Bhat, PharmD, on the Role of the Clinical Pharmacist in IBD
07/25/2024
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent...
07/25/2024
Advances in Inflammatory Bowel Disease Network
Jessica Allegretti
Video
Jessica Allegretti, MD, on Recent Advances in Anti-Interleukin Therapies
07/19/2024
Dr Allegretti provides key take-home points from her presentation at the AIBD regional meeting on how anti-interleukin therapies work to treat both Crohn's disease and ulcerative colitis.
Dr Allegretti provides key take-home points from her presentation at the AIBD regional meeting on how anti-interleukin therapies work to treat both Crohn's disease and ulcerative colitis.
Dr Allegretti provides key...
07/19/2024
Advances in Inflammatory Bowel Disease Network
Ed Loftus
Video
Edward Loftus, MD, on Upadacitinib in Crohn's Disease
06/06/2024
Dr Loftus recaps his poster presentation on a subanalysis from the upadacitinib phase 3 trials in Crohn's disease examining the effect on anxiety, depression, fatigue, and bowel urgency.
Dr Loftus recaps his poster presentation on a subanalysis from the upadacitinib phase 3 trials in Crohn's disease examining the effect on anxiety, depression, fatigue, and bowel urgency.
Dr Loftus recaps his poster...
06/06/2024
Advances in Inflammatory Bowel Disease Network
Miguel Regueiro MD
Conference Coverage
Miguel Regueiro, MD, on the SEQUENCE Study
06/03/2024
Miguel D. Regueiro, MD
Dr Regueiro recaps the results from the pivotal study comparing the effects of risankizumab with ustekinumab on key biomarkers of inflammatory bowel disease, which he presented at Digestive Disease Week 2024.
Dr Regueiro recaps the results from the pivotal study comparing the effects of risankizumab with ustekinumab on key biomarkers of inflammatory bowel disease, which he presented at Digestive Disease Week 2024.
Dr Regueiro recaps the results...
06/03/2024
Advances in Inflammatory Bowel Disease Network
Rishika Chugh
Podcast
Rishika Chugh, MD: Safety of Vedolizumab and Ustekinumab in Pregnancy
05/28/2024
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of...
05/28/2024
Advances in Inflammatory Bowel Disease Network
Christina Ha
Video
Christina Ha, MD, on Anti-Integrins in IBD
04/27/2024
Dr Ha recaps her presentation from the AIBD regional on the use of anti-integrins, particularly vedolizumab, for treating IBD.
Dr Ha recaps her presentation from the AIBD regional on the use of anti-integrins, particularly vedolizumab, for treating IBD.
Dr Ha recaps her presentation...
04/27/2024
Advances in Inflammatory Bowel Disease Network
Ray
Video
Raymond Cross, MD, on JAK Inhibitors in IBD
04/27/2024
Dr Cross reviews his presentation from the AIBD regional meeting on the use, safety, and positioning of Janus kinase inhibitors for the treatment of IBD.
Dr Cross reviews his presentation from the AIBD regional meeting on the use, safety, and positioning of Janus kinase inhibitors for the treatment of IBD.
Dr Cross reviews his...
04/27/2024
Advances in Inflammatory Bowel Disease Network
Jordan Axelrad
Conference Coverage
Jordan Axelrad, MD, on S1P Receptor Modulators in IBD
04/06/2024
Dr Axelrad discusses his presentation at the AIBD regional meeting on the value and positioning of sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease.
Dr Axelrad discusses his presentation at the AIBD regional meeting on the value and positioning of sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease.
Dr Axelrad discusses his...
04/06/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Russell Cohen, MD, on New Therapies for IBD
12/20/2023
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive...
12/20/2023
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Jennifer Seminerio, MD, on Advanced Combination Therapy
06/12/2026
Raymond Cross, MD; Jennifer Seminerio, MD
Drs Cross and Seminerio discuss advanced combination therapy, which involves use of more than one biologic or a biologic and an advanced small molecule, including trial results to date, types of combinations, safety considerations, and which...
Drs Cross and Seminerio discuss advanced combination therapy, which involves use of more than one biologic or a biologic and an advanced small molecule, including trial results to date, types of combinations, safety considerations, and which...
Drs Cross and Seminerio discuss...
06/12/2026
Advances in Inflammatory Bowel Disease Network
Gil Melmed
Conference Coverage
Gil Melmed, MD, on Prehabilitation Among IBD Surgical Patients
06/01/2026
Gil Y. Melmed, MD
Dr Melmed reviews the prehabilitation protocol trialed at Cedars-Sinai among patients with IBD who were preparing for surgery, which showed a definite reduction in complications among the cohort that received multidisciplinary care as well as...
Dr Melmed reviews the prehabilitation protocol trialed at Cedars-Sinai among patients with IBD who were preparing for surgery, which showed a definite reduction in complications among the cohort that received multidisciplinary care as well as...
Dr Melmed reviews the...
06/01/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Jordan Axelrad, MD, on Communicating Risks to Patients With IBD
05/22/2026
Raymond Cross, MD; Jordan Axelrad, MD
Drs Raymond Cross and Jordan Axelrad provide guidance to clinicians about the best ways to put risks—both of uncontrolled IBD and of therapies—into perspective for patients.
Drs Raymond Cross and Jordan Axelrad provide guidance to clinicians about the best ways to put risks—both of uncontrolled IBD and of therapies—into perspective for patients.
Drs Raymond Cross and Jordan...
05/22/2026
Advances in Inflammatory Bowel Disease Network
Bruce Sands
Expert Insights
Bruce Sands, MD, on Results from DUET-CD
05/19/2026
Bruce E. Sands, MD, MS
Dr Sands reviews the results of the DUET-CD study of combination therapy with guselkumab and golimumab in patients with Crohn's disease, which showed a significant increase in efficacy for the combination versus either drug independently.
Dr Sands reviews the results of the DUET-CD study of combination therapy with guselkumab and golimumab in patients with Crohn's disease, which showed a significant increase in efficacy for the combination versus either drug independently.
Dr Sands reviews the results of...
05/19/2026
Advances in Inflammatory Bowel Disease Network
Maria Abreu
Research Insights
Maria Abreu, MD, on the DUET-UC Trial of Combination Therapy
05/19/2026
Maria Abreu, MD
Dr Abreu recaps the results of a late breaking abstract from Digestive Disease Week on the DUET-UC study, which tested whether a combination of two advanced therapies showed an additive or synergistic effect in patients refractory ulcerative...
Dr Abreu recaps the results of a late breaking abstract from Digestive Disease Week on the DUET-UC study, which tested whether a combination of two advanced therapies showed an additive or synergistic effect in patients refractory ulcerative...
Dr Abreu recaps the results of a...
05/19/2026
Advances in Inflammatory Bowel Disease Network
Miguel Regueiro MD
Research Review
Miguel Regueiro, MD, on Therapies for Perianal Crohn's Disease
05/13/2026
Miguel D. Regueiro, MD
Dr Regueiro reviews his presentation from Digestive Disease Week on the treatment of perianal Crohn's disease, including advances in medical therapies and surgical approaches. 
Dr Regueiro reviews his presentation from Digestive Disease Week on the treatment of perianal Crohn's disease, including advances in medical therapies and surgical approaches. 
Dr Regueiro reviews his...
05/13/2026
Advances in Inflammatory Bowel Disease Network
Stephen Hanauer
Conference Coverage
Stephen Hanauer, MD, on Themes in IBD at DDW
05/07/2026
Stephen B. Hanauer, MD
Dr Hanauer reviews the key themes that were discussed in sessions on inflammatory bowel diseases at Digestive Diseases Week 2026, including prevention, early treatment, and combination therapy.
Dr Hanauer reviews the key themes that were discussed in sessions on inflammatory bowel diseases at Digestive Diseases Week 2026, including prevention, early treatment, and combination therapy.
Dr Hanauer reviews the key...
05/07/2026
Advances in Inflammatory Bowel Disease Network
Jean-Frederic Colombel
Expert Insights
Jean-Frederic Colombel, MD, on Disease Clearance With Mirikizumab in Ulcerative Colitis
05/06/2026
Jean-Frederic Colombel
Dr Colombel discusses his presentation at DDW 2026 on a post-doc analysis of the long-term outcomes of the LUCENT trial of mirikizumab, which showed that the IL-23p19 inhibitor achieved and maintained disease clearance for up to 4 years among...
Dr Colombel discusses his presentation at DDW 2026 on a post-doc analysis of the long-term outcomes of the LUCENT trial of mirikizumab, which showed that the IL-23p19 inhibitor achieved and maintained disease clearance for up to 4 years among...
Dr Colombel discusses his...
05/06/2026
Advances in Inflammatory Bowel Disease Network
Ed Barnes
Conference Coverage
Edward Barnes, MD on the VIVID Trials of Mirikizumab in Bio-Exposed Patients With Crohn's Disease
05/06/2026
Edward L. Barnes, MD
Dr Barnes reviewed his presentation of results from the VIVID 1 and VIVID 2 trials of mirkizumab in patients with Crohn's disease with exposure to anti-TNF therapy, which found that 65% of those in endoscopic response at week 52 maintained...
Dr Barnes reviewed his presentation of results from the VIVID 1 and VIVID 2 trials of mirkizumab in patients with Crohn's disease with exposure to anti-TNF therapy, which found that 65% of those in endoscopic response at week 52 maintained...
Dr Barnes reviewed his...
05/06/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Colleen Kelly, MD, on Obesity and IBD
04/20/2026
Raymond Cross, MD; Colleen Kelly, MD
Host Raymond Cross, MD, calls on Dr Colleen Kelly to discuss the increasing prevalence of obesity among patients with IBD, how obesity can complicate Crohn's disease and ulcerative colitis, and the role of GLP-1 RAs and bariatric surgery in...
Host Raymond Cross, MD, calls on Dr Colleen Kelly to discuss the increasing prevalence of obesity among patients with IBD, how obesity can complicate Crohn's disease and ulcerative colitis, and the role of GLP-1 RAs and bariatric surgery in...
Host Raymond Cross, MD, calls on...
04/20/2026
Advances in Inflammatory Bowel Disease Network

Interactive Features

Quiz
Role of Biologic Agents in IBD
06/14/2023
Priyam Vora
Are biologic agents the ultimate answer in the treatment of intestinal inflammation? Test your knowledge here!
Are biologic agents the ultimate answer in the treatment of intestinal inflammation? Test your knowledge here!
Are biologic agents the ultimate...
06/14/2023
Advances in Inflammatory Bowel Disease Network
Quiz
Terminal Ileal Resection and CRC Risk
08/07/2025
Rebecca Mashaw
Is terminal ileum resection in patients with Crohn’s disease associated with colorectal cancer risk? See what recent research found by taking our quiz.
Is terminal ileum resection in patients with Crohn’s disease associated with colorectal cancer risk? See what recent research found by taking our quiz.
Is terminal ileum resection in...
08/07/2025
Gastroenterology
Quiz
Does Hormone Replacement Therapy Affect IBD?
07/18/2025
Can hormone replacement therapy help or harm disease activity among women with IBD? Our quiz will show the answer!
Can hormone replacement therapy help or harm disease activity among women with IBD? Our quiz will show the answer!
Can hormone replacement therapy...
07/18/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Can Perspiration Reveal IBD Biomarkers?
07/18/2025
Can a wearable sensor help monitor disease activity in IBD--via sweat? Take our quiz to get the answer.
Can a wearable sensor help monitor disease activity in IBD--via sweat? Take our quiz to get the answer.
Can a wearable sensor help...
07/18/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Making EHRs Work
07/01/2025
Rebecca Mashaw
Which of the following factors did clinicians say in a recent study is particularly important for EHR functionality in the context of IBD?
Which of the following factors did clinicians say in a recent study is particularly important for EHR functionality in the context of IBD?
Which of the following factors...
07/01/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Do EHRs Help or Hinder in IBD Care?
07/01/2025
Rebecca Mashaw
According to a recent survey of clinicians who care for patients with inflammatory bowel disease, what percentage reported that their EHR system does not enhance patient care in IBD?
According to a recent survey of clinicians who care for patients with inflammatory bowel disease, what percentage reported that their EHR system does not enhance patient care in IBD?
According to a recent survey of...
07/01/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Advanced Combination Treatment for Refractory IBD
07/01/2025
Rebecca Mashaw
A multicenter Canadian study to evaluate advanced combination treatment (ACT) in patients with refractory inflammatory bowel disease (IBD) arrived at which of the following conclusions?
A multicenter Canadian study to evaluate advanced combination treatment (ACT) in patients with refractory inflammatory bowel disease (IBD) arrived at which of the following conclusions?
A multicenter Canadian study to...
07/01/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Biomarkers in Perspiration
07/01/2025
A recent study evaluated the use of a wearable sensor to measure inflammatory biomarkers in perspiration as a noninvasive method for monitoring IBD activity. What did it show? Take our quiz to see if you know the answer!
A recent study evaluated the use of a wearable sensor to measure inflammatory biomarkers in perspiration as a noninvasive method for monitoring IBD activity. What did it show? Take our quiz to see if you know the answer!
A recent study evaluated the use...
07/01/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Hormone Replacement Impact on IBD
05/22/2025
Rebecca Mashaw
Does hormone replacement therapy have any effect on treatment for IBD among postmenopausal women? Take our quiz to find out!
Does hormone replacement therapy have any effect on treatment for IBD among postmenopausal women? Take our quiz to find out!
Does hormone replacement therapy...
05/22/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Upper GI Crohn's Disease
03/18/2025
Rebecca Mashaw
How much do you know about upper GI Crohn's disease? Take our quiz to check your knowledge!
How much do you know about upper GI Crohn's disease? Take our quiz to check your knowledge!
How much do you know about upper...
03/18/2025
Advances in Inflammatory Bowel Disease Network
Quiz
Preoperative Nutrition for Crohn’s Disease Patients
03/18/2025
Rebecca Mashaw
What is one benefit of preoperative exclusive enteral nutrition for Crohn’s disease patients? Take our quiz to find out if you know the answer!
What is one benefit of preoperative exclusive enteral nutrition for Crohn’s disease patients? Take our quiz to find out if you know the answer!
What is one benefit of...
03/18/2025
Advances in Inflammatory Bowel Disease Network

Latest News

FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
Standard Dosing of Infliximab Effective for Steroid-Refractory ASUC
10/18/2024
Jessica Garlewicz
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and...
10/18/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Guselkumab for Moderate to Severe Ulcerative Colitis
09/12/2024
Rebecca Mashaw
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab is the first and only fully-human, dual-acting monoclonal antibody that blocks IL-23 and binds to CD64.
Johnson & Johnson’s guselkumab...
09/12/2024
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Requires Warning Label Change for Thiopurines
08/13/2024
Rebecca Mashaw
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare cases of intrahepatic cholestasis of pregnancy have been reported among pregnant patients treated with thiopurines for inflammatory bowel disease and systemtic lupus erythematosus.
The agency stated that rare...
08/13/2024
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib vs Tofacitinib for Clinical Remission in Ulcerative Colitis
08/09/2024
Jolynn Tumolo
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a head-to-head trial of the 2 JAK inhibitors to determine which performed best in achieving steroid-free clinical remission among patients with ulcerative colitis
Investigators conducted a...
08/09/2024
Advances in Inflammatory Bowel Disease Network
News
FDA Approves Interchangeable Biosimilar for Ustekinumab
11/02/2023
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
The biosimilar was also approved...
11/02/2023
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Mirikizumab for Adults With Moderately to Severely Active Ulcerative Colitis
10/27/2023
Rebecca Mashaw
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated the safety and efficacy of the interleukin-23/p19 subunit inhibitor.
The LUCENT trial demonstrated...
10/27/2023
Advances in Inflammatory Bowel Disease Network
News
FDA Approves New Oral Treatment for Ulcerative Colitis
10/13/2023
Priyam Vora
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug Administration approved etrasimod for the treatment of moderate to severe ulcerative colitis among adults.
The U.S. Food and Drug...
10/13/2023
Advances in Inflammatory Bowel Disease Network
Research Highlights
Combined Ultrasound and Calprotectin at 3 Months Predict Postoperative Recurrence in Crohn’s Disease
05/07/2026
Jessica Garlewicz
High specificity and positive predictive value suggest that patients meeting both thresholds are at high risk for early recurrence and may need closer monitoring.
High specificity and positive predictive value suggest that patients meeting both thresholds are at high risk for early recurrence and may need closer monitoring.
High specificity and positive...
05/07/2026
Advances in Inflammatory Bowel Disease Network
News
Oral Icotrokinra Demonstrates Efficacy in Ulcerative Colitis Regardless of Prior Advanced Therapy Exposure
05/05/2026
Jessica Garlewicz
While response rates were generally higher in patients without prior advanced therapy failure, meaningful improvements were still seen in those with treatment-resistant disease.
While response rates were generally higher in patients without prior advanced therapy failure, meaningful improvements were still seen in those with treatment-resistant disease.
While response rates were...
05/05/2026
Advances in Inflammatory Bowel Disease Network
Research Review
Early “Top-Down” Therapy Reduces Long-Term Complications in Crohn’s Disease
05/05/2026
Jessica Garlewicz
Disease progression and hospitalizations were more common in the step-up group, with higher rates of stricturing and penetrating complications.
Disease progression and hospitalizations were more common in the step-up group, with higher rates of stricturing and penetrating complications.
Disease progression and...
05/05/2026
Advances in Inflammatory Bowel Disease Network
Research Review
Upper GI Crohn’s Disease Remains Underrecognized, Lacks Standardized Guidance
04/02/2026
Jessica Garlewicz
A recent review noted a lack of consistent diagnostic definitions across modalities, complicating clinical interpretation and research comparisons.
A recent review noted a lack of consistent diagnostic definitions across modalities, complicating clinical interpretation and research comparisons.
A recent review noted a lack of...
04/02/2026
Advances in Inflammatory Bowel Disease Network
Research Summary
Advanced Therapy May Reduce Antibiotic Dependence in Chronic Pouchitis After IPAA
03/18/2026
Jessica Garlewicz
These findings support considering immune-mediated therapy in selected patients although more research is needed to identify the patients likely to benefit most from advanced therapy.
These findings support considering immune-mediated therapy in selected patients although more research is needed to identify the patients likely to benefit most from advanced therapy.
These findings support...
03/18/2026
Advances in Inflammatory Bowel Disease Network
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
News
Medicare Will Cover GLP-1s for Obesity Under Deal with Pharma
11/06/2025
Rebecca Mashaw
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said the new lower prices also will be provided for Medicaid programs, with prices and timing decided state by state as they opt in.
Administration officials said...
11/06/2025
Advances in Inflammatory Bowel Disease Network
FDA alert
FDA Alert
FDA Approves Updated Indication for Upadacitinib in IBD
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Concomitant Medications Do Not Alter Efficacy of Advanced Therapies in Ulcerative Colitis, Study Finds
09/18/2025
Jessica Garlewicz
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Persistent Prothrombotic State Observed in Patients With ASUC
09/04/2025
Rebecca Mashaw
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with...
09/04/2025
Advances in Inflammatory Bowel Disease Network

Latest Podcasts

IBD Drive time logo
Podcast
IBD Drive Time: Erin Forster, MD, on Risankizumab for Ulcerative Colitis
09/03/2024
Erin Forster, MD, MPH; Millie D. Long, MD, MPH; Raymond Cross, MD
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical...
09/03/2024
Advances in Inflammatory Bowel Disease Network
Shubha Bhat
Podcast
Shubha Bhat, PharmD, on the Role of the Clinical Pharmacist in IBD
07/25/2024
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent...
07/25/2024
Advances in Inflammatory Bowel Disease Network
Rishika Chugh
Podcast
Rishika Chugh, MD: Safety of Vedolizumab and Ustekinumab in Pregnancy
05/28/2024
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of a recent study of the safety of ustekinumab and vedolizumab among pregnant patients with inflammatory bowel disease.
Dr Chugh reviews the results of...
05/28/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Russell Cohen, MD, on New Therapies for IBD
12/20/2023
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive Time, Dr Raymond Cross and Dr Russell Cohen review several new therapies and formulations that have been recently approved for treating inflammatory bowel disease and discuss how best to position these medications.
In this episode of IBD Drive...
12/20/2023
Advances in Inflammatory Bowel Disease Network
Bruce Sands
Podcast
Bruce Sands, MD, on the VEGA Study of Combination Biologic Therapy in UC
12/19/2022
Dr Sands provides an overview of the VEGA study, the first of its kind to combine 2 biologic agents to attempt to achieve higher rates of remission among patients with ulcerative colitis.
Dr Sands provides an overview of the VEGA study, the first of its kind to combine 2 biologic agents to attempt to achieve higher rates of remission among patients with ulcerative colitis.
Dr Sands provides an overview of...
12/19/2022
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Jennifer Seminerio, MD, on Advanced Combination Therapy
06/12/2026
Raymond Cross, MD; Jennifer Seminerio, MD
Drs Cross and Seminerio discuss advanced combination therapy, which involves use of more than one biologic or a biologic and an advanced small molecule, including trial results to date, types of combinations, safety considerations, and which...
Drs Cross and Seminerio discuss advanced combination therapy, which involves use of more than one biologic or a biologic and an advanced small molecule, including trial results to date, types of combinations, safety considerations, and which...
Drs Cross and Seminerio discuss...
06/12/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Jordan Axelrad, MD, on Communicating Risks to Patients With IBD
05/22/2026
Raymond Cross, MD; Jordan Axelrad, MD
Drs Raymond Cross and Jordan Axelrad provide guidance to clinicians about the best ways to put risks—both of uncontrolled IBD and of therapies—into perspective for patients.
Drs Raymond Cross and Jordan Axelrad provide guidance to clinicians about the best ways to put risks—both of uncontrolled IBD and of therapies—into perspective for patients.
Drs Raymond Cross and Jordan...
05/22/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Colleen Kelly, MD, on Obesity and IBD
04/20/2026
Raymond Cross, MD; Colleen Kelly, MD
Host Raymond Cross, MD, calls on Dr Colleen Kelly to discuss the increasing prevalence of obesity among patients with IBD, how obesity can complicate Crohn's disease and ulcerative colitis, and the role of GLP-1 RAs and bariatric surgery in...
Host Raymond Cross, MD, calls on Dr Colleen Kelly to discuss the increasing prevalence of obesity among patients with IBD, how obesity can complicate Crohn's disease and ulcerative colitis, and the role of GLP-1 RAs and bariatric surgery in...
Host Raymond Cross, MD, calls on...
04/20/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Jared Magee, MD, on Men's Health in IBD
04/07/2026
Raymond Cross, MD; Jared Magee, MD
Drs Raymond Cross and Jared Magee discuss some of the special concerns that affect men with inflammatory bowel disease, from cardiac concerns to sexual dysfunction and assessing for anal cancer.
Drs Raymond Cross and Jared Magee discuss some of the special concerns that affect men with inflammatory bowel disease, from cardiac concerns to sexual dysfunction and assessing for anal cancer.
Drs Raymond Cross and Jared...
04/07/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: The Best of ECCO 2026
03/25/2026
Raymond Cross, MD; Sara Horst, MD; Jordan Axelrad, MD
Host Raymond Cross, MD, is joined by Drs Sara Horst and Jordan Axelrad to review the findings of their picks for the best presentations from the European Crohn's and Colitis Organization meeting held earlier this year.
Host Raymond Cross, MD, is joined by Drs Sara Horst and Jordan Axelrad to review the findings of their picks for the best presentations from the European Crohn's and Colitis Organization meeting held earlier this year.
Host Raymond Cross, MD, is...
03/25/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Shirley Cohen-Mekelburg, MD on Self-Care for IBD Patients
03/17/2026
Shirley Cohen-Mekelburg; Raymond Cross, MD
Host Raymond Cross, MD, calls on Dr Shirley Mekelburg-Cohen to discuss the importance of self-care among patients with IBD, what self-care consists of, and how to help patients learn to partner with their clinicians in controlling their...
Host Raymond Cross, MD, calls on Dr Shirley Mekelburg-Cohen to discuss the importance of self-care among patients with IBD, what self-care consists of, and how to help patients learn to partner with their clinicians in controlling their...
Host Raymond Cross, MD, calls on...
03/17/2026
Advances in Inflammatory Bowel Disease Network
New IBD Logo
Expert Insights
IBD Drive Time: James Lewis, MD, on Dysplasia Surveillance in IBD
02/23/2026
Raymond Cross, MD; James D. Lewis, MD
Dr James Lewis from the University of Pennsylvania and host Dr Raymond Cross discuss the risk of colon cancer among patients with inflammatory bowel disease, the importance of appropriate surveillance, and special considerations for choosing...
Dr James Lewis from the University of Pennsylvania and host Dr Raymond Cross discuss the risk of colon cancer among patients with inflammatory bowel disease, the importance of appropriate surveillance, and special considerations for choosing...
Dr James Lewis from the...
02/23/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Expert Insights
IBD Drive Time: Raymond Cross, MD, on Ostomy Complications
01/13/2026
Raymond Cross, MD; Sara Horst, MD
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
In this episode of IBD Drive Time, Dr Raymond Cross switches seats and acts as the guest with Sara Horst, MD, as host, to discuss the complexities of ostomy complications.
In this episode of IBD Drive...
01/13/2026
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Conference Coverage
IBD Drive Time: The Best of ACG With Dr Sara Horst
12/01/2025
Raymond Cross, MD; Sara Horst, MD
Dr Sara Horst joins IBD Drive Time host Dr Raymond Cross to review their choices for the best presentations from the American College of Gastroenterology annual meeting.
Dr Sara Horst joins IBD Drive Time host Dr Raymond Cross to review their choices for the best presentations from the American College of Gastroenterology annual meeting.
Dr Sara Horst joins IBD Drive...
12/01/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive Time
Podcast
IBD Drive Time: Freddy Caldera, MD, on Vaccines for Patients With IBD
11/03/2025
Raymond Cross, MD; Freddy Caldera, DO
Freddy Caldera, DO, returns to talk to IBD Drive Time host Raymond Cross, MD, about the best current recommendations for patients with IBD in the midst of controversy and confusion.
Freddy Caldera, DO, returns to talk to IBD Drive Time host Raymond Cross, MD, about the best current recommendations for patients with IBD in the midst of controversy and confusion.
Freddy Caldera, DO, returns to...
11/03/2025
Advances in Inflammatory Bowel Disease Network

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use